Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer
Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Overall, 77 of 124 patients had PSA declines of more than 50% with surgery or stereotactic body radiation therapy (SBRT). In particular, […]